Market Cap$33.61B
P/E22.06x
PEG Ratio1.37
Div yield1.25%
Beta0.77
RMD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-6.32%
Price vs S&P 500 (4W)8.19%
PEG Ratio1.37
VGM Score60.01
P/E Ratio (Annual)22.06x
Indicated Dividend Yield (Annual)1.25%
RMD Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.89 | $2.95 | +1.98%(+$0.06) | |
| Q1 2026 | $2.80 | $2.86 | +2.15%(+$0.06) | |
| Q4 2025 | $2.72 | $2.81 | +3.15%(+$0.09) | |
| Q3 2025 | $2.50 | $2.55 | +2.05%(+$0.05) | |
| Q2 2025 | $2.48 | $2.55 | +2.77%(+$0.07) |
RMD Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.64
3.60
3.48
3.52
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
| PENPenumbra, Inc. | F | C | B | 8.4x | 20.2% | 67.8% | 12.4% | $320.86 |
About ResMed Inc.
ResMed is a global leader in respiratory care devices for sleep apnea treatment, with structural growth tailwinds from rising diagnoses, aging populations, and increasing obesity prevalence. The company generates approximately two-thirds of revenue from the Americas, with the remainder from Europe, Japan, and Australia. ResMed is building competitive differentiation through digital health platforms that deliver clinical data to patients, healthcare providers, and payers in out-of-hospital settings.